5-Hydroxytryptamine and the pathophysiology of migraine

Journal of Neurology

Volumn 238, Issue 1 Supplement, 1991, Pages

  Humphrey, P P A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 Hydroxytryptamine; Antimigraine drugs; Pathophysiology; Serotonin; Sumatriptan

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; AMITRIPTYLINE; BEMESETRON; CYPROHEPTADINE; DIHYDROERGOTAMINE; ERGOTAMINE TARTRATE; KETANSERIN; METHYSERGIDE; PIZOTIFEN; PROPRANOLOL; RITANSERIN; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SPIPERONE; SUMATRIPTAN; TROPISETRON;

CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; PRIORITY JOURNAL;

CEREBROVASCULAR DISORDERS; HUMAN; MIGRAINE; SEROTONIN;

EID: 0025907027     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/BF01642905     Document Type: Article

References (91)

1. Pathophysiology of 5-hydroxytryptamine: an overview
2. Plasma serotonin in migraine and stress
3. The possible relationship of serotonin to the migraine syndrome
4. Effect of ergotamine on cardiovascular catecholamine receptors in the pithed rat
5. m-Chlorophenylpiperazine increases blood pressure and heart rate in pithed and conscious rats
6. The site of pain origin during migraine attacks
7. Migraine and intracranial swelling: an experiment of nature
8. Citalopram versus maprotiline: a controlled, clinical, multicentre trial in depressed patients
9. Craniovascular studies in headache: a report and analysis of pulse volume trainings
10. Induction of migraine-like headaches by the serotonin agonist m-chlorophenylpiperazine
11. The anti-migraine drug sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater
12. The effects of reserpine injection on methysergide treated control and migrainous subjects
13. Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine
14. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy- m-methoxymandelic acid excretion in normal and migrainous subjects
15. Clinical trial of methysergide and other preparations in the management of migraine
16. The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects
17. Excretion of 5-hydroxyindolyl acetic acid (5HIAA) in migraine
18. Fenfluramine headache: a biochemical and monoamine receptorial human study
19. Extracranial vascular changes and the source of pain in migraine headache
20. Release of platelet 5-hydroxytryptamine by plasma taken from patients during and between migraine attacks
21. What is migraine? Controversy and stalemate in migraine pathophysiology
22. Rationale for the use of 5-HT1-like agonists in the treatment of migraine
23. 5-HT3 receptor antagonists and migraine therapy
24. Methionine-enkephalin and serotonin in migraine and tension headache
25. Urinary excretion of biogenic amines camines in migraine and tension headache
26. Serotonin metabolism in migraine
27. The animal pharmacology of drugs used in the treatment of migraine
28. Serotonin, migraine and platelets
29. 5-HT in migraine: evidence from 5-HT receptor antagonists for a neuronal aetiology
30. 5-HT1C receptor activation: a key step in the initiation of migraine?
31. Cerebral blood flow changes in migraine: methods, observations and hypotheses
32. Concentration of serotonin in blood platelets: effect of reserpine in migraineurs
33. Mechanism of migraine
34. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial
35. Mechanism of migraine headache and action of ergotamine tartrate
36. Ergotamine and cerebral blood flow
37. Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery
38. Calcitonin gene-related peptide is present in mammalian cerebrovascular nerve fibers and dilates pial and peripheral arteries
39. Pathogenesis of migraine
40. New product in the treatment of migraine; preliminary report
41. Molecular pharmacology and biology of 5-HT1C receptors
42. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (−)-[125H]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin
43. Ketanserin — a novel hypertensive drug?
44. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175
45. Sumatriptan succinate
46. A rational approach to identifying a fundamentally new drug for the treatment of migraine
47. Anti-migraine drugs in development: advances in serotonin receptor pharmacology
48. 5-HT in migraine: evidence from 5-HT1-like receptor agonists for a vascular aetiology
49. Serotonin and migraine
50. Pharmacological characterisation of 5-hydroxytryptamine-induced depolarisation of the rat isolated vagus nerve
51. Effect of serotonin in migraine patients
52. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome
53. Efficacy and tolerability of ICS 205-930, a 5-HT3 receptor antagonist, in migraine prophylaxis
54. Effects on migraine headache of MDL 72222 an antagonist at neuronal 5-HT receptors. Double-blind, placebocontrolled study
55. Neurobiology of vascular head pain
56. Sensory connections to cephalic blood vessels and their possible importance to vascular headaches
57. Neurotransmitters and the fifth cranial nerve: is there a relation to headache phase of migraine?
58. Platelet serotonin (5-HT) and 5-HT releasing factor in plasma of migrainous patients
59. Basic pharmacological properties
60. 5-HT2 receptor antagonists and migraine therapy
61. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries
62. Migraine and regional cerebral blood flow
63. Spreading cerebral oligemia in classical and normal cerebral blood flow in common migraine
64. Studies in headache
65. Studies on headache: arterenol (norepinephrine) and vascular headache of the migraine type
66. Serotonin (5-hydroxytryptamine)
67. The pharmacology of current anti-migraine drugs
68. Sumatriptan (GR43175) interacts selectively with 5-HT1B and 5-HT1D binding sites
69. Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine
70. Serotonin-releasing effects of substituted piperazines in vitro
71. Pharmacology of migraine
72. Experimental studies on headache: Pain-sensitive structures of the head and their significance in headache
73. A comparison between fluoxetine and doxepine in depressed patients
74. Identification of 5-hydroxytryptamine M-receptor subtypes and their specific blockade by a new class of drugs
75. Double-blind crossover comparison of BC-105, methysergide and placebo in the prophylaxis of migraine headache
76. A putative 5-HT central feedback in migraine and cluster headache attacks
77. Experimental studies on headache: A. Contrast of histamine headache with the headache of migraine and that associated with hypertension. B. Contrast of vascular mechanisms in preheadache and in headache phenomena of migraine
78. Prophylactic and therapeutic properties of l-methyl-lysergic acid butanolamide in migraine
79. Biochemical investigations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks
80. Severe headache and disturbed liver function during treatment with zimelidine
81. Migraine headache and blood serotonin levels after administration of zimelidine, a selective inhibitor of serotonin uptake
82. Die Beeinflussung migräneartiger Zustände durch ein sympathikushemmendes Mittel (Gynergen)
83. Le traitement des migraines par le tartrate d'ergotamine
84. The distribution and biochemistry of 5-hydroxytryptamine in the cardiovascular system
85. Ketanserin — a selective serotonin antagonist, in relation to platelet aggregation and migraine attack rate